The goal of Dr. Nording's lab is to use mass spectrometry (MS) methods for molecular phenotyping and translate the findings for benefit in the clinic. A major focus has been on integration of multiple analytical platforms to study comprehensive metabolite profiles and thereby determine the relationship between disrupted metabolism and adverse outcomes, for instance in response to air pollution exposure in humans. In this metabolomics context, pain and inflammation have also been studied with emphasis on bioactive lipid mediators.
Dr. Nording has a leading role in the Hyperemesis Or nausea in PrEgnancy (HOPE) study with the goal to develop a new framwork for personalised medicine to facilitate treatment tailored to each individual hyperemesis gravidarum (HG) patient. The Nording lab contributes with new knowledge in the field of MS-driven translational science with the mission to develop curative treatment for HG. For more information about the research, please see HOPE.